Viewing Study NCT00988169


Ignite Creation Date: 2025-12-24 @ 10:46 PM
Ignite Modification Date: 2026-02-20 @ 6:41 PM
Study NCT ID: NCT00988169
Status: TERMINATED
Last Update Posted: 2015-11-20
First Post: 2009-09-30
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None AT-101 View
None erlotinib View
None Unresectable Stage IIIB View
None 09-026 View